Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE

ConclusionReal-world ubrogepant use with an anti-CGRP monoclonal antibody was associated with MPR, RNF, satisfaction, and acute treatment optimization.

http://link.springer.com/10.1007/s40120-023-00556-8

Source: Neurology and Therapy - November 1, 2023 Category: Neurology Source Type: research